Ozempic approved for distribution in Jamaica

Key Points(5)
- Ozempic, a prescription medication used to treat Type 2 diabetes and support weight loss, has been approved for distribution in Jamaica as the Government moves to expand treatment options for obesity.
- Minister of Health and Wellness Dr.
- Christopher Tufton made the disclosure while addressing the launch of the Ministry’s Lifestyle Clinic at the Sandy Bay Health Centre in Hanover on November 12.
- Ozempic contains semaglutide, a medication belonging to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists.
- It works by mimicking a naturally occurring hormone that helps regulate blood sugar levels, slows the movement of food through the stomach and reduces appetite, allowing patients to feel fuller for longer.
Jamaica has approved the distribution of Ozempic, a prescription medication widely used to manage Type 2 diabetes and support weight loss, as the government moves to expand treatment options for people living with obesity.
Minister of Health and Wellness Dr. Christopher Tufton made the announcement during the launch of the Ministry's Lifestyle Clinic at the Sandy Bay Health Centre in Hanover on November 12.
Ozempic contains semaglutide, an active ingredient belonging to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs mimic a naturally occurring hormone that helps regulate blood sugar levels, slows digestion and reduces appetite, allowing patients to feel fuller for longer.
Manufactured by Danish pharmaceutical company Novo Nordisk, Ozempic is administered through a once-weekly injection. Although primarily developed to treat Type 2 diabetes, the medication has gained international attention for its effectiveness in helping some patients lose weight.
Semaglutide is also the active ingredient in Wegovy, another medication manufactured by Novo Nordisk that is specifically approved for chronic weight management in certain patients. Unlike Ozempic, which is primarily approved for diabetes treatment in markets such as the United States, Wegovy is prescribed at doses intended for weight management.
The medications have become increasingly popular worldwide amid growing interest in pharmaceutical treatments for obesity, a condition associated with an increased risk of heart disease, stroke, Type 2 diabetes and other chronic illnesses.
However, Ozempic is not suitable for everyone. Common side effects include nausea, vomiting, diarrhea, constipation and abdominal discomfort. More serious complications, including pancreatitis and gallbladder problems, can also occur. Health professionals recommend that patients use the medication only under medical supervision.
Tufton said other branded medications used to manage obesity are also being considered for approval in Jamaica.
“We hope that by next year, they will be approved, and also the generic equivalent to those,” he said, noting that the medications will be available through pharmacies.
The minister acknowledged that some Jamaicans seeking obesity treatment have been purchasing these medications through informal channels, including from overseas suppliers, often at inflated prices.
“What used to happen in the past is that it was a black market. People used to buy it in Miami and those places or wherever, and take in and sell it at [higher] costs,” he pointed out.
“So, over the next quarter or so, those drugs should be available, and the generic version would be the cheaper version,” he stated.
Tufton also indicated that consideration would be given to facilitating access to the medications through the National Health Fund (NHF), potentially making treatment more affordable for eligible patients.
Meanwhile, the newly launched Lifestyle Clinic at the Sandy Bay Health Centre will target individuals whose health is at risk because of obesity.
Patients will be referred to the clinic by doctors following medical assessments and will receive support from a multidisciplinary team of specialists, including psychologists, nutritionists, physical activity specialists and social workers.
The initiative is designed to help patients adopt healthier lifestyles, manage their weight and reduce their risk of developing serious chronic illnesses.
Tufton cautioned that medications such as Ozempic should not be viewed as substitutes for healthy lifestyle practices, emphasizing that obesity management requires a comprehensive approach involving proper nutrition, regular physical activity and medical supervision.
“That’s part of controlling obesity. It’s not the full picture. So, I’m not here prescribing the one solution to the problem,” he said.






